GHK-Cu Peptide Extends Worm Lifespan by Boosting Mitochondria and Stress Response
Background
Aging is a complex biological process characterized by progressive functional decline and increased susceptibility to age-related diseases, with oxidative stress being a key contributing factor. Glycine-Histidine-Lysine (GHK), a naturally occurring tripeptide often complexed with copper (GHK-Cu), is known for its regenerative and protective properties. However, its precise mechanisms for delaying aging and extending lifespan, particularly concerning mitochondrial function and key longevity pathways, remain underexplored.
Study Design
Results
The study revealed that GHK-Cu significantly extended the lifespan of C. elegans compared to untreated controls. Mechanistically, GHK-Cu preserved mitochondrial function by increasing mitochondrial membrane potential and alleviating age-related mitochondrial network fragmentation. It also shifted mitochondrial dynamics toward fusion by regulating drp-1 and fzo-1 gene expression, and promoted ATP biosynthesis. Furthermore, GHK-Cu activated the DAF-16 (a FOXO transcription factor) and SKN-1 (a Nrf2 homolog) pathways, which are critical for stress resistance and longevity. GHK-Cu demonstrated a coordinated anti-aging effect by both enhancing mitochondrial health and activating the DAF-16 and SKN-1 longevity pathways, leading to a notable extension of organismal lifespan compared to untreated controls.
Why It Matters
This research highlights GHK-Cu as a promising compound with significant anti-aging potential, acting through fundamental cellular mechanisms. The findings suggest that targeting mitochondrial health and activating conserved longevity pathways like DAF-16 and SKN-1 could be a viable strategy for combating age-related decline. Further investigation into GHK-Cu's effects in mammalian models could pave the way for novel therapeutic interventions to promote healthy aging in humans. Future steps would involve preclinical studies to confirm these benefits and safety in more complex organisms, potentially leading to human clinical trials.